| Issue Date | Title | Author(s) |
| 2011 | Arginase inhibitor in the pharmacological correction of endothelial dysfunction | Pokrovskiy, M. V.; Korokin, M. V.; Tsepeleva, S. A.; Pokrovskaya, T. G.; Kochkarov, V. I. |
| 2022 | Cytokines in abdominal aortic aneurysm: master regulators with clinical application | Puchenkova, O. A.; Soldatov, V. O.; Deykin, A. V.; Korokin, M. V.; Pokrovskiy, M. V. |
| 2022 | Development and validation of eltrombopag determination in human plasma Blood by HPLC-MS Method | AL-Dhuraibi, A. M.; Kulikov, A. L.; Pokrovskiy, M. V. |
| 2018 | Dyssynchrony of the heart as a pathogenetic mechanism of the chronic cardiac insufficiency progression on the backgroound of ischemic heart disease or physiological aging of the heart | Osipova, O. A.; Zhernakova, N. I.; Askari, I. V.; Bukatov, V. V.; Pokrovskiy, M. V. |
| 2018 | Effect of antagonist mineralocorticoid receptors Eplerenon on the dynamics of QT interval dispersion in patients with acute elderly aged | Shekhovtsova, L. V.; Osipova, O. A.; Zhernakova, N. I.; Pokrovskiy, M. V.; Pokrovskaya, T. G. |
| 2019 | Effect of multipotent mesenchymal stromal cells secretome on imiquimod-induced psoriasis in rats | Nadezhdina, N. A.; Nadezhdin, S. V.; Bondarev, V. P.; Mycic, A. V.; Burda, Yu. E.; Pokrovskiy, M. V.; Danilenko, L. M.; Peresypkina, A. A. |
| 2021 | Evaluation of eltrombopag efficacy in patients with hepatitis C-induced thrombocytopenia: systematic reviews of meta-analysis | AL-Dhuraibi, A. M.; Pokrovskiy, M. V.; Abakumov, A. K.; AL-Dhuraibi, W. M. |
| 2018 | Experimental approaches to the assessment of potential cardioprotective means with doxorubicin-associated cardiomyopathy | Danilenko, L. M.; Pokrovskiy, M. V.; Kotelnikova, A. S.; Timokhina, A. S.; Zhernakova, N. I. |
| 2020 | Increased Expression of the Multimerin-1 Gene in α-Synuclein Knokout Mice | Chaprova, K. D.; Goloborshcheva, V. V.; Korokin, M. V.; Soldatov, V. O.; Pokrovskiy, M. V. |
| 2020 | Non-hematopoietic erythropoietin-derived peptides for atheroprotection and treatment of cardiovascular diseases | Belyaeva, V. S.; Stepenko, Yu. V.; Kulikov, A. L.; Kochkarova, I. S.; Martynova, O. V.; Pokrovskiy, M. V. |
| 2019 | Pharmacological preconditioning by incretinomimetics exenatide and vildagliptin: decrement of liver ischemia-reperfusion injury | Tarasova, A. P.; Pokrovskiy, M. V.; Trunov, K. S.; Danilenko, A. P.; Stepenko, Yu. V.; Batischeva, G. A.; Galenko-Yaroshevskiy, P. A. |
| 2021 | Retinal abnormalities in transgenic mice overexpressing aberrant human FUS[1-359] gene | Soldatov, V. O.; Kukharsky, M. S.; Puchenkova, O. A.; Deykin, A. V.; Pokrovskiy, M. V. |
| 2021 | Safety and efficacy of eltrombopag in patients with chronic immune thrombocytopenia: meta-analysis of randomized controlled trials | Al-Dhuraibi, A. M.; Al-Dhuraibi, W. M.; Abakumov, A. K.; Soldatov, V.; Pokrovskiy, M. V. |
| 2015 | Simulation of total brain ischemia in rats | Martynova, O. V.; Gureev, V. V.; Pokrovskiy, M. V.; Martynov, M. A.; Solgalova, A. S. |
| 2019 | Stimulation of reparation in a linear wound model in rats by Bischofit gel | Stepenko, Yu. V.; Soldatov, V. O.; Demidenko, A. N.; Ivahno, E. N.; Sarycheva, M. V.; Pokrovskiy, M. V. |
| 2018 | The definition of specific antiparkinsonian effects of Rapitalam | Avdeeva, N. V.; Pokrovskiy, M. V.; Zhernakova, N. I.; Artyushkova, E. B. |
| 2019 | Tissue distribution of potential antidiabetic agent C7070 | Kulikov, A. L.; Pokrovskiy, M. V.; Kulikova, S. Y.; Kochkarova, I. S.; Dubcova, E. Yu. |
| 2021 | Triple-knockout, synuclein-free mice display compromised lipid pattern | Guschina, I. A.; Ninkina, N.; Roman, A.; Pokrovskiy, M. V.; Buchman, V. L. |
